Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Completed without a posted recruiting period Show 4 more changesShow less
    • Primary completion date changed from estimate of Feb 2026 to Mar 30, 2026
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2025 to Dec 8, 2025
    • Eligibility criteria expanded, about 34 words
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this study is to investigate the safety and tolerability of YN001 in combination with rosuvastatin, so as to provide evidence for the feasibility of YN001 combined with statins in subsequent clinical trials.
Trial Details
NCT Number NCT07309042
Lead Sponsor Beijing Inno Medicine Co., Ltd.
Conditions
(from sponsor)		 Atherosclerotic Cardiovascular Diseases, Cerebrovascular Diseases
Related terms Cerebrovascular Disorders
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov